Showing results (81-90 of 115) with videos related to

Sort By:
Pageof 12
The Journal of Dermatology|March 11, 2025
Deucravacitinib in plaque psoriasis: Safety and efficacy through 3 years in Japanese patients in the phase 3 POETYK PSO-1, PSO-4, and LTE trialsAkimichi Morita, Shinichi Imafuku, Yayoi Tada, et al.
The Journal of Dermatology|October 26, 2024
First reported case of thymoma-associated multiorgan autoimmunity induced by COVID-19Rie Hyobu, Miho Mori, Tatsuo Maeda, et al.
Experimental Dermatology|March 17, 2026
Complications and Laboratory Test Findings Among Patients With Generalized Pustular Psoriasis: A Retrospective Chart Review StudyRyuhei Okuyama, Yukari Okubo, Shinichi Imafuku, et al.
The Journal of Dermatology|February 27, 2016
Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese studyShinichi Imafuku, Masaru Honma, Yukari Okubo, et al.
Acta Dermato-Venereologica|April 20, 2026
An Exploratory Study to Identify Factors Associated with Recurrence of Generalized Pustular Psoriasis Flares in Adult Patients in JapanAkimichi Morita, Yukari Okubo, Ryuhei Okuyama, et al.
Current Issues in Molecular Biology|July 28, 2026
Regulation of Imiquimod-Induced Mouse Psoriasis Development via Apoptosis Signal-Regulating Kinase 1 Potentially by Antagonizing Aryl Hydrocarbon Receptor ExpressionHideaki Hasegawa, Aruma Watanabe, Yasuhiro Katahira, et al.
Journal of Dermatological Science|December 25, 2010
Quantification of activated and total caspase-14 with newly developed ELISA systems in normal and atopic skinMami Yamamoto, Yayoi Kamata, Toshii Iida, et al.
The Journal of Dermatology|April 30, 2025
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Plaque Psoriasis: In-Depth Analysis of Efficacy and Safety in the Phase 3 POETYK PSO-4 TrialYukari Okubo, Akimichi Morita, Shinichi Imafuku, et al.
The Journal of Dermatology|December 6, 2024
Deucravacitinib in Japanese patients with plaque, generalized pustular, or erythrodermic psoriasis: Patient-reported outcomes in the POETYK PSO-4 studyYayoi Tada, April W Armstrong, Shinichi Imafuku, et al.
The Journal of Dermatology|February 25, 2021
Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1)Atsuyuki Igarashi, Hidemi Nakagawa, Akimichi Morita, et al.
Pageof 12